💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Ajooni Biotech Limited is an animal health care solutions company. The Company is specialized in compounded animal feed and feed supplements. Its portfolio offers a wide range of quality cattle feed; cattle feed chips, camel feed, cotton oil cake, mustard oil cake and a wide…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, fast-growing business, reasonably priced — but flagged on governance.
AJOONI BIOTECH is scored on the general / industrial framework. It keeps a thin 2.3% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT -1.33×) — worth a closer look. Free cash flow is worth about -40.1% of its market value.
Over the last 3 years revenue compounded at 35%/yr and profit at 57%/yr. Book value itself has compounded 30%/yr — the hallmark of a genuine compounder. Return on equity is a weak 4.7%. In the latest quarter profit fell 55% versus the prior quarter.
At 12× earnings, the stock sits at the 29th percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price asks for only ~3%/yr growth over a decade — undemanding expectations. The forensic screen raises a red flag: Only ₹-1.86 of cash per ₹1 profit over 4 years — earnings not converting to cash.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 13.45 | 68.08 | better |
| P/B | 0.56 | 1.76 | better |
| EV/EBITDA | 7.69 | 31.87 | better |
| ROE | 4.74 | 10.5 | worse |
| ROCE | 5.92 | — | — |
| ROA | 3.29 | — | — |
| Quick Ratio | 1.26 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Hindustan Unilever | 31.1 | 9.6 | 22.9% |
| ITC | 18.4 | 5.0 | 26.4% |
| Nestle India | 60.5 | 42.7 | 70.6% |
Revenue has grown every year across all 4 financial years shown. 35% CAGR over 3 years — high-growth territory. Growth is accelerating — latest year outpaced the prior year's rate.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (57% vs 35%) — margin expansion is at work.
Operating margins have been stable around 3% — no major structural shift.
ROE at 5% — modest; the capital isn't working hard. Low variance across years — a predictable business that earns steadily on its equity base.
Profit grew faster than EPS (57% vs -49%) — share dilution is eroding per-share value. -49% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
3 of 4 years had negative operating cash flow — profitability on paper may not translate to cash.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Wide quarterly swings (50% spread) — likely seasonality, lumpy orders, or project-based revenue. Run-rate stepping up — recent quarters average 38% above earlier ones.
Profit fell 55% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly margins are compressing (3% → 1%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 30.5% — dispersed ownership; institutional flows drive the stock. Promoters added 3.6pp over 4 quarters — creeping acquisition signals conviction.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.